Literature DB >> 19576519

Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas.

Gangadhara Reddy Sareddy1, Manas Panigrahi, Sundaram Challa, Anita Mahadevan, Phanithi Prakash Babu.   

Abstract

Astrocytomas are the most common form of primary brain tumors. Understanding the molecular basis of development and progression of astrocytomas is required to develop more effective therapies. Although, over activation of Wnt/beta-catenin/Tcf pathway is a hallmark of several forms of cancer, little is known about its role in human astrocytomas. Here, we report the evidence that Wnt/beta-catenin/Tcf signaling pathway is constitutively activated in astrocytic tumors. In the present study, human astrocytic tumors with different clinical grades were analyzed for mRNA expression of Dvl-1, Dvl-2, Dvl-3, beta-catenin, c-myc and cyclin D1 and protein levels of beta-catenin, Lef1, Tcf4, c-Myc, N-Myc, c-jun and cyclin D1. RT-PCR analysis demonstrated the overexpression of Dvl-3, beta-catenin, c-myc and cyclin D1 in astrocytomas. Western blotting revealed upregulation of beta-catenin, Lef1, Tcf4 and their target proteins in the core tumor tissues in comparison to peritumor and normal brain tissues. The protein and mRNA levels were positively correlated with the histological malignancy. Cytoplasmic and nuclear accumulation of beta-catenin, nuclear localization of Lef1, Tcf4, c-Myc, N-Myc, c-jun and cyclin D1 were demonstrated by immunohistochemical staining. Our studies tend to suggest that Wnt/beta-catenin/Tcf signaling pathway is implicated in malignancy of astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576519     DOI: 10.1016/j.neuint.2009.03.016

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  55 in total

1.  High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

Authors:  Junxia Zhang; Kai Huang; Zhendong Shi; Jian Zou; Yingyi Wang; Zhifan Jia; Anling Zhang; Lei Han; Xiao Yue; Ning Liu; Tao Jiang; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

3.  Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Authors:  Mireia Náger; Maria Santacana; Deepshikha Bhardwaj; Joan Valls; Isidre Ferrer; Pere Nogués; Carles Cantí; Judit Herreros
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.

Authors:  Gisela N Castro; Niubys Cayado-Gutiérrez; Vera L Moncalero; Patricia Lima; Rodolfo Lucero De Angelis; Victor Chávez; F Darío Cuello-Carrión; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2012-07-18       Impact factor: 3.667

5.  Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells.

Authors:  Gangadhara Reddy Sareddy; Divya Kesanakurti; Puligurtha Bharadhwaja Kirti; Phanithi Prakash Babu
Journal:  Neurochem Res       Date:  2013-09-08       Impact factor: 3.996

Review 6.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

7.  MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Authors:  Shaofang Wu; Shuzhen Wang; Siyuan Zheng; Roel Verhaak; Dimpy Koul; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2016-04-22       Impact factor: 6.261

8.  Expression and aberrant promoter methylation of Wnt inhibitory factor-1 in human astrocytomas.

Authors:  Zhuanyi Yang; Ying Wang; Jiasheng Fang; Fenghua Chen; Jinfang Liu; Jun Wu; Yanjin Wang
Journal:  J Exp Clin Cancer Res       Date:  2010-03-24

9.  Differentiation of the brain vasculature: the answer came blowing by the Wnt.

Authors:  Stefan Liebner; Karl H Plate
Journal:  J Angiogenes Res       Date:  2010-01-14

10.  Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin.

Authors:  Kui Wang; James O Park; Miqin Zhang
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.